Biomarker-guided Antibiotic Therapy-strengths and Limitations

Overview

Journal Ann Transl Med

Publisher AME Publishing Company

Date 2017 Jun 13

PMID 28603723

Citations 31

Authors

David Nora

Jorge Salluh

Ignacio Martin-Loeches

Pedro Povoa

Affiliations

Soon will be listed here.

Abstract

Biomarkers as C-reactive protein (CRP) and procalcitonin (PCT) emerged as tools to help clinicians to diagnose infection and to properly initiate and define the duration of antibiotic therapy. Several randomized controlled trials, including adult critically ill patients, showed that PCT-guided antibiotic stewardship was repeatedly associated with a decrease in the duration of antibiotic therapy with no apparent harm. There are however some relevant limitations in these trials namely the low rate of compliance of PCT-guided algorithms, the high rate of exclusion (without including common clinical situations and pathogens) and the long duration of antibiotic therapy in control groups. Such limitations weakened the real impact of such algorithms in the clinical decision-making process and strengthened the concept that the initiation and the duration of antibiotic therapy cannot depend solely on a biomarker. Future efforts should address these limitations in order to better clarify the role of biomarkers on the complex and multifactorial issue of antibiotic management and to deeply understand its potential effect on mortality.

Citing Articles

Diagnosis of neonatal and adult sepsis using a Serum Amyloid A lateral flow test.

Nowak J, Ssanyu J, Namiiro F, Mountford N, Parducci A, Domijan K PLoS One. 2025; 20(2):e0314702.

PMID: 39937751 PMC: 11819581. DOI: 10.1371/journal.pone.0314702.

Antibiotic duration for common bacterial infections-a systematic review.

Mo Y, Tan W, Cooper B JAC Antimicrob Resist. 2025; 7(1):dlae215.

PMID: 39881797 PMC: 11775593. DOI: 10.1093/jacamr/dlae215.

Efficacy and safety of an algorithm using C-reactive protein to guide antibiotic therapy applied through a digital clinical decision support system: a study protocol for a randomised controlled clinical trial.

Rezende V, Borges I, Ravetti C, de Souza R, Vassalo P, Caldas A BMJ Open. 2025; 15(1):e084981.

PMID: 39870501 PMC: 11772927. DOI: 10.1136/bmjopen-2024-084981.

Usefulness of Serum Biomarkers in Predicting Anastomotic Leakage After Gastrectomy.

Ramos D, Gallego-Colon E, Minguez J, Bodega I, Priego P, Garcia-Moreno F Cancers (Basel). 2025; 17(1.

PMID: 39796753 PMC: 11720279. DOI: 10.3390/cancers17010125.

Identification and experimental validation of diagnostic and prognostic genes CX3CR1, PID1 and PTGDS in sepsis and ARDS using bulk and single-cell transcriptomic analysis and machine learning.

Jiang J, Chen Y, Su Y, Zhang L, Qian H, Song X Front Immunol. 2025; 15:1480542.

PMID: 39763654 PMC: 11700820. DOI: 10.3389/fimmu.2024.1480542.

References

Oliveira C, Botoni F, Oliveira C, Silva C, Pereira H, Serufo J . Procalcitonin versus C-reactive protein for guiding antibiotic therapy in sepsis: a randomized trial. Crit Care Med. 2013; 41(10):2336-43. DOI: 10.1097/CCM.0b013e31828e969f. View

Ali Kiaei B, Ghiasi F, Moradi D . Precalcitonin and C-reactive protein as markers in response to antibiotic treatment in ventilator-associated pneumonia in intensive care unit-hospitalized patients. Adv Biomed Res. 2015; 4:240. PMC: 4673706. DOI: 10.4103/2277-9175.168607. View

Jensen J, Heslet L, Jensen T, Espersen K, Steffensen P, Tvede M . Procalcitonin increase in early identification of critically ill patients at high risk of mortality. Crit Care Med. 2006; 34(10):2596-602. DOI: 10.1097/01.CCM.0000239116.01855.61. View

Schroeder S, Hochreiter M, Koehler T, Schweiger A, Bein B, Keck F . Procalcitonin (PCT)-guided algorithm reduces length of antibiotic treatment in surgical intensive care patients with severe sepsis: results of a prospective randomized study. Langenbecks Arch Surg. 2008; 394(2):221-6. DOI: 10.1007/s00423-008-0432-1. View

. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001; 69(3):89-95. DOI: 10.1067/mcp.2001.113989. View

Strykowski D, Nielsen A, Llor C, Siersma V, Bjerrum L . An intervention with access to C-reactive protein rapid test reduces antibiotic overprescribing in acute exacerbations of chronic bronchitis and COPD. Fam Pract. 2015; 32(4):395-400. DOI: 10.1093/fampra/cmv020. View

de Jong E, van Oers J, Beishuizen A, Vos P, Vermeijden W, Haas L . Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. Lancet Infect Dis. 2016; 16(7):819-827. DOI: 10.1016/S1473-3099(16)00053-0. View

Cho S, Choi J . Biomarkers of sepsis. Infect Chemother. 2014; 46(1):1-12. PMC: 3970312. DOI: 10.3947/ic.2014.46.1.1. View

Deliberato R, Marra A, Sanches P, Martino M, Dos Santos Ferreira C, Pasternak J . Clinical and economic impact of procalcitonin to shorten antimicrobial therapy in septic patients with proven bacterial infection in an intensive care setting. Diagn Microbiol Infect Dis. 2013; 76(3):266-71. DOI: 10.1016/j.diagmicrobio.2013.03.027. View

10.

Schuetz P, Muller B, Christ-Crain M, Stolz D, Tamm M, Bouadma L . Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev. 2012; (9):CD007498. PMC: 6464976. DOI: 10.1002/14651858.CD007498.pub2. View

11.

Huddy J, Ni M, Barlow J, Majeed A, Hanna G . Point-of-care C reactive protein for the diagnosis of lower respiratory tract infection in NHS primary care: a qualitative study of barriers and facilitators to adoption. BMJ Open. 2016; 6(3):e009959. PMC: 4785316. DOI: 10.1136/bmjopen-2015-009959. View

12.

Canovi M, Lucchetti J, Stravalaci M, Valentino S, Bottazzi B, Salmona M . A new surface plasmon resonance-based immunoassay for rapid, reproducible and sensitive quantification of pentraxin-3 in human plasma. Sensors (Basel). 2014; 14(6):10864-75. PMC: 4118366. DOI: 10.3390/s140610864. View

13.

Jensen J, Hein L, Lundgren B, Bestle M, Mohr T, Andersen M . Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: a randomized trial. Crit Care Med. 2011; 39(9):2048-58. DOI: 10.1097/CCM.0b013e31821e8791. View

14.

Povoa P, Salluh J . Use of biomarkers in sepsis: many questions, few answers. Rev Bras Ter Intensiva. 2013; 25(1):1-2. PMC: 4031864. DOI: 10.1590/s0103-507x2013000100001. View

15.

Zilahi G, Artigas A, Martin-Loeches I . What's new in multidrug-resistant pathogens in the ICU?. Ann Intensive Care. 2016; 6(1):96. PMC: 5053965. DOI: 10.1186/s13613-016-0199-4. View

16.

Schuetz P, Albrich W, Mueller B . Procalcitonin for diagnosis of infection and guide to antibiotic decisions: past, present and future. BMC Med. 2011; 9:107. PMC: 3186747. DOI: 10.1186/1741-7015-9-107. View

17.

Hunter R . Cost-effectiveness of point-of-care C-reactive protein tests for respiratory tract infection in primary care in England. Adv Ther. 2015; 32(1):69-85. PMC: 4311066. DOI: 10.1007/s12325-015-0180-x. View

18.

Oppong R, Jit M, Smith R, Butler C, Melbye H, Molstad S . Cost-effectiveness of point-of-care C-reactive protein testing to inform antibiotic prescribing decisions. Br J Gen Pract. 2013; 63(612):e465-71. PMC: 3693803. DOI: 10.3399/bjgp13X669185. View

19.

Annane D, Maxime V, Faller J, Mezher C, Clech C, Martel P . Procalcitonin levels to guide antibiotic therapy in adults with non-microbiologically proven apparent severe sepsis: a randomised controlled trial. BMJ Open. 2013; 3(2). PMC: 3586059. DOI: 10.1136/bmjopen-2012-002186. View

20.

Westwood M, Ramaekers B, Whiting P, Tomini F, Joore M, Armstrong N . Procalcitonin testing to guide antibiotic therapy for the treatment of sepsis in intensive care settings and for suspected bacterial infection in emergency department settings: a systematic review and cost-effectiveness analysis. Health Technol Assess. 2015; 19(96):v-xxv, 1-236. PMC: 4781547. DOI: 10.3310/hta19960. View